New York-based AI drug discovery startup Ordaos Bio has raised USD 5 million in an oversubscribed seed funding round led by led by Middleland Capital's VTC Ventures with participation from Route 66 Ventures, Banyan Pacific Capital, and others. This round brings the company’s total funds raised to date to USD 10.6 million.
The proceeds will be directed toward fueling the company’s product development and expand its partner base.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.